Evicenter
MarkdownMedical informationP&T meetings
Obefazimod (ABX464)

Ulcerative colitis

Manufacturer
Abivax
Launch
Not announced
Last updated
173 sources

Clinical evidence

ABTECT-1

87 evidence topics · 20 sources

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using clinical remission by modified mayo score as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Participants analyzed by arm in the posted results
PopulationABX464 50 mgABX464 25 mgPlaceboTotal
Started“318”“161”“160”Not reported
Baseline (Full Analysis Set)“318”“160”“158”“636”
Primary and secondary endpoints (Full Analysis Set)“318”“160”“158”Not reported
Adverse events (at risk)“0/318 (0.00%)”“0/160 (0.00%)”“0/158 (0.00%)”Not reported
Description of analysis sets
Results
Participant disposition
Participant flow by arm in the posted results
DispositionABX464 50 mgABX464 25 mgPlacebo
Started“318”“161”“160”
Completed“291”“155”“143”
Not completed“27”“6”“17”
Adverse event“18”“0”“6”
Lost to follow-up“1”“1”“1”
Never dosed“0”“1”“1”
Non-compliance with study drug“2”“0”“0”
Physician decision“1”“0”“1”
Protocol violation“1”“0”“1”
Withdrawal by subject“4”“4”“7”
Pooled ABTECT-1 and ABTECT-2: study discontinuation and reasons
DispositionObefazimod 50 mgObefazimod 25 mgPlacebo
Participants who discontinued the study, n (%)“54 (8.5)”“23 (7.2)”“31 (9.7)”
Adverse event, n (% of discontinuations)“31 (57.4)”“8 (34.8)”“14 (45.2)”
Withdrawal by subject“13 (24.1)”“10 (43.5)”“10 (32.3)”
Lack of efficacy“2 (3.7)”“2 (8.7)”“1 (3.2)”
Lost to follow-up“4 (7.4)”“1 (4.3)”“1 (3.2)”
Baseline characteristics
Baseline characteristics by arm in the posted results
CharacteristicABX464 50 mg (n=318)ABX464 25 mg (n=160)Placebo (n=158)Total (n=636)
Age, years, mean (SD)“42.7(14.3)”“41.5(13.54)”“43.1(13.59)”“42.5(13.93)”
Age 65 years or older, participants“25”“12”“11”“48”
Female, participants“129”“56”“66”“251”
Male, participants“189”“104”“92”“385”
Asian, participants“87”“34”“45”“166”
Black or African American, participants“5”“3”“2”“10”
White, participants“219”“114”“106”“439”
Weight, kg, mean (SD)“72.41(18.581)”“72.58(17.269)”“71.28(16.392)”“72.17(17.713)”
Duration of ulcerative colitis, years, mean (SD)“7.98(7.348)”“7.8(7.151)”“7.51(7.761)”“7.82(7.395)”
At least one prior advanced therapy inadequate response, participants“149”“70”“69”“288”
Inadequate response to JAK inhibitors among those with AT-IR, participants“22”“15”“15”“52”
Modified Mayo Score, mean (SD)“6.9(1.06)”“6.8(1.04)”“6.9(1.04)”“6.9(1.05)”
Mayo endoscopic subscore 2, participants“128”“69”“64”“261”
Mayo endoscopic subscore 3, participants“190”“91”“94”“375”
Fecal calprotectin, µg/g, mean (SD)“3768.46(6219.12)”“2533.58(3761.06)”“5390.53(9479.94)”“3828.77(6729.81)”
Pooled ABTECT-1 and ABTECT-2: treatment exposure
ExposureObefazimod 50 mg (n=636)Obefazimod 25 mg (n=319)Placebo (n=317)
Duration of exposure, days, mean (SD)“58.8 (12.62)”“59.5 (11.14)”“58.7 (11.14)”
Duration of exposure, days, median [min, max]“60.0 [1, 106]”“61.0 [4, 96]”“61.0 [5, 102]”
Efficacy results
Primary and key secondary endpoints at Week 8
Endpoint at Week 8, % (n)Placebo (N=158)Obefazimod 25 mg (N=160)Obefazimod 50 mg (N=318)25 mg minus placebo, %25 mg p-value50 mg minus placebo, %50 mg p-value
Clinical remission (primary)“2.5 (4)”View highlighted excerpt for this quote“23.8 (38)”View highlighted excerpt for this quote“21.7 (69)”View highlighted excerpt for this quote“21.4”View highlighted excerpt for this quote“p < 0.0001”View highlighted excerpt for this quote“19.3”View highlighted excerpt for this quote“p < 0.0001”View highlighted excerpt for this quote
Clinical response“28.5 (45)”View highlighted excerpt for this quote“65.6 (105)”View highlighted excerpt for this quote“61.0 (194)”View highlighted excerpt for this quote“37.2”View highlighted excerpt for this quote“p < 0.0001”View highlighted excerpt for this quote“32.6”View highlighted excerpt for this quote“p < 0.0001”View highlighted excerpt for this quote
Endoscopic improvement“5.7 (9)”View highlighted excerpt for this quote“37.5 (60)”View highlighted excerpt for this quote“33.3 (106)”View highlighted excerpt for this quote“32.0”View highlighted excerpt for this quote“p < 0.0001”View highlighted excerpt for this quote“27.8”View highlighted excerpt for this quote“p < 0.0001”View highlighted excerpt for this quote
HEMI“3.2 (5)”View highlighted excerpt for this quote“23.8 (38)”View highlighted excerpt for this quote“23.0 (73)”View highlighted excerpt for this quote“20.7”View highlighted excerpt for this quote“p < 0.0001”View highlighted excerpt for this quote“20.0”View highlighted excerpt for this quote“p < 0.0001”View highlighted excerpt for this quote
Symptomatic remission“17.7 (28)”View highlighted excerpt for this quote“42.5 (68)”View highlighted excerpt for this quote“41.2 (131)”View highlighted excerpt for this quote“24.9”View highlighted excerpt for this quote“p < 0.0001”View highlighted excerpt for this quote“23.7”View highlighted excerpt for this quote“p < 0.0001”View highlighted excerpt for this quote
Participants meeting each endpoint at Week 8 in the posted results
Endpoint at Week 8, participantsABX464 50 mg (n=318)ABX464 25 mg (n=160)Placebo (n=158)
Clinical remission per modified Mayo Score (primary)“69”“38”“4”
Endoscopic improvement“106”“60”“9”
Clinical response per modified Mayo Score“194”“105”“45”
HEMI per Geboes“73”“38”“5”
Pooled ABTECT-1 and ABTECT-2: primary and secondary endpoints at Week 8
Endpoint at Week 8, % (n)Placebo (N=317)Obefazimod 25 mg (N=319)Obefazimod 50 mg (N=636)25 mg minus placebo, %50 mg minus placebo, %
Clinical remission“4.4 (14)”View highlighted excerpt for this quote“17.6 (56)”View highlighted excerpt for this quote“20.8 (132)”View highlighted excerpt for this quote“13.2”View highlighted excerpt for this quote“16.4”View highlighted excerpt for this quote
Clinical response“30.9 (98)”View highlighted excerpt for this quote“59.6 (190)”View highlighted excerpt for this quote“62.1 (395)”View highlighted excerpt for this quote“28.6”View highlighted excerpt for this quote“31.2”View highlighted excerpt for this quote
Endoscopic improvement“7.9 (25)”View highlighted excerpt for this quote“29.8 (95)”View highlighted excerpt for this quote“34.4 (219)”View highlighted excerpt for this quote“21.9”View highlighted excerpt for this quote“26.6”View highlighted excerpt for this quote
HEMI“5.4 (17)”View highlighted excerpt for this quote“18.5 (59)”View highlighted excerpt for this quote“23.4 (149)”View highlighted excerpt for this quote“13.2”View highlighted excerpt for this quote“18.2”View highlighted excerpt for this quote
Symptomatic remission“19.9 (63)”View highlighted excerpt for this quote“37.9 (121)”View highlighted excerpt for this quote“40.7 (259)”View highlighted excerpt for this quote“18.1”View highlighted excerpt for this quote“21.0”View highlighted excerpt for this quote
Subgroups by prior advanced therapy inadequate response at Week 8 (nominal p-values)
Endpoint at Week 8, % (n)AT-IR-Yes placebo (N=69)AT-IR-Yes 25 mg (N=70)AT-IR-Yes 50 mg (N=149)AT-IR-No placebo (N=89)AT-IR-No 25 mg (N=90)AT-IR-No 50 mg (N=169)
Clinical remission“1.4 (1)”View highlighted excerpt for this quote“8.6 (6)”View highlighted excerpt for this quote“14.1 (21)”View highlighted excerpt for this quote“3.4 (3)”View highlighted excerpt for this quote“35.6 (32)”View highlighted excerpt for this quote“28.4 (48)”View highlighted excerpt for this quote
Endoscopic improvement“4.3 (3)”View highlighted excerpt for this quote“14.3 (10)”View highlighted excerpt for this quote“22.1 (33)”View highlighted excerpt for this quote“6.7 (6)”View highlighted excerpt for this quote“55.6 (50)”View highlighted excerpt for this quote“43.2 (73)”View highlighted excerpt for this quote
Symptomatic remission“10.1 (7)”View highlighted excerpt for this quote“27.1 (19)”View highlighted excerpt for this quote“34.9 (52)”View highlighted excerpt for this quote“23.6 (21)”View highlighted excerpt for this quote“54.4 (49)”View highlighted excerpt for this quote“46.7 (79)”View highlighted excerpt for this quote
HEMI“1.4 (1)”View highlighted excerpt for this quote“5.7 (4)”View highlighted excerpt for this quote“12.8 (19)”View highlighted excerpt for this quote“4.5 (4)”View highlighted excerpt for this quote“37.8 (34)”View highlighted excerpt for this quote“32.0 (54)”View highlighted excerpt for this quote
Clinical response“21.7 (15)”View highlighted excerpt for this quote“52.9 (37)”View highlighted excerpt for this quote“54.4 (81)”View highlighted excerpt for this quote“33.7 (30)”View highlighted excerpt for this quote“75.6 (68)”View highlighted excerpt for this quote“66.9 (113)”View highlighted excerpt for this quote
Pooled ABTECT-1 and ABTECT-2: subgroups by prior advanced therapy inadequate response at Week 8 (nominal p-values)
Endpoint at Week 8, % (n)AT-IR-Yes placebo (N=148)AT-IR-Yes 25 mg (N=146)AT-IR-Yes 50 mg (N=308)AT-IR-No placebo (N=169)AT-IR-No 25 mg (N=173)AT-IR-No 50 mg (N=328)
Clinical remission“3.4 (5)”View highlighted excerpt for this quote“6.8 (10)”View highlighted excerpt for this quote“13.3 (41)”View highlighted excerpt for this quote“5.3 (9)”View highlighted excerpt for this quote“26.6 (46)”View highlighted excerpt for this quote“27.7 (91)”View highlighted excerpt for this quote
Endoscopic improvement“6.8 (10)”View highlighted excerpt for this quote“13.0 (19)”View highlighted excerpt for this quote“24.4 (75)”View highlighted excerpt for this quote“8.9 (15)”View highlighted excerpt for this quote“43.9 (76)”View highlighted excerpt for this quote“43.9 (144)”View highlighted excerpt for this quote
Symptomatic remission“12.8 (19)”View highlighted excerpt for this quote“26.7 (39)”View highlighted excerpt for this quote“36.0 (111)”View highlighted excerpt for this quote“26.0 (44)”View highlighted excerpt for this quote“47.4 (82)”View highlighted excerpt for this quote“45.1 (148)”View highlighted excerpt for this quote
HEMI“4.1 (6)”View highlighted excerpt for this quote“6.8 (10)”View highlighted excerpt for this quote“14.9 (46)”View highlighted excerpt for this quote“6.5 (11)”View highlighted excerpt for this quote“28.3 (49)”View highlighted excerpt for this quote“31.4 (103)”View highlighted excerpt for this quote
Clinical response“20.9 (31)”View highlighted excerpt for this quote“46.6 (68)”View highlighted excerpt for this quote“55.8 (172)”View highlighted excerpt for this quote“39.6 (67)”View highlighted excerpt for this quote“70.5 (122)”View highlighted excerpt for this quote“68.0 (223)”View highlighted excerpt for this quote
Pooled ABTECT-1 and ABTECT-2: clinical response by prior JAK inhibitor failure and number of failed advanced therapies (nominal p-values)
Subset of AT-IR participantsPlacebo, % (n/N)Obefazimod 25 mg, % (n/N)25 mg minus placebo, % and p-valueObefazimod 50 mg, % (n/N)50 mg minus placebo, % and p-value
Prior JAK inhibitor failure“20.0 (7/35)”View highlighted excerpt for this quote“47.1 (16/34)”View highlighted excerpt for this quote“27.0 p = 0.0196”View highlighted excerpt for this quote“54.5 (30/55)”View highlighted excerpt for this quote“34.4 p = 0.0017”View highlighted excerpt for this quote
1 advanced therapy failure“24.2 (15/62)”View highlighted excerpt for this quote“53.3 (24/45)”View highlighted excerpt for this quote“30.5 p = 0.0018”View highlighted excerpt for this quote“50.7 (76/150)”View highlighted excerpt for this quote“25.3 p = 0.0008”View highlighted excerpt for this quote
2 advanced therapy failures“20.6 (7/34)”View highlighted excerpt for this quote“48.9 (22/45)”View highlighted excerpt for this quote“28.6 p = 0.0114”View highlighted excerpt for this quote“67.2 (43/64)”View highlighted excerpt for this quote“45.5 p < 0.0001”View highlighted excerpt for this quote
3 advanced therapy failures“14.3 (4/28)”View highlighted excerpt for this quote“42.4 (14/33)”View highlighted excerpt for this quote“27.3 p = 0.0297”View highlighted excerpt for this quote“61.5 (32/52)”View highlighted excerpt for this quote“46.3 p < 0.0001”View highlighted excerpt for this quote
4 or more advanced therapy failures“20.8 (5/24)”View highlighted excerpt for this quote“34.8 (8/23)”View highlighted excerpt for this quote“14.4 p = 0.2968”View highlighted excerpt for this quote“50.0 (21/42)”View highlighted excerpt for this quote“28.7 p = 0.0242”View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
Pooled ABTECT-1 and ABTECT-2: disease-specific and overall quality of life (IBDQ and EQ-5D-5L)

“The IBDQ has four domains, scores range 32-224; higher scores=better QoL. Meaningful within patient change (MWPC) for IBDQ total score was defined as ≥ 16 point change and remission as ≥ 170 points.” (opens the source at this quote in a new tab)

“All p-values are nominal.” (opens the source at this quote in a new tab)

“1272 pts were randomized and treated in ABTECT-1 (n = 636) and ABTECT-2 (n = 636); 1207 had IBDQ, 1137 had EQ-5D-5L Index and 1,180 had EQ-5D-5L VAS data at baseline.” (opens the source at this quote in a new tab)

“At baseline, pts had mean IBDQ total scores of 110.8, 110.8, and 109.7 for Obe-50, Obe-25, and PBO, respectively. At Week 8, Obe-treated pts reported higher mean IBDQ scores vs PBO: 161.9, 159.2, and 135.7 in the Obe-50, Obe-25 and PBO groups respectively (Obe-50:Δ25.97 and Obe-25:Δ22.33, p < 0.0001).” (opens the source at this quote in a new tab)

“At Week 8, a greater proportion of Obe-treated pts had a MWPC: 60.9% for Obe-50 and 56.9% for Obe-25 vs 39.8% for PBO (Obe-50:Δ21.20 and Obe-25:Δ17.07, p < 0.0001). More Obe-treated pts without IBDQ remission at baseline achieved IBDQ remission: 36.7% for Obe-50 and 33.2% for Obe-25 vs 19.6% for PBO (Obe-50:Δ17.13 and Obe-25:Δ13.56, p < 0.001).” (opens the source at this quote in a new tab)

“At baseline, mean EQ-5D-5L Index scores were 0.66, 0.64, and 0.63 for Obe-50, Obe-25, and PBO, respectively. At Week 8, Obe-treated pts reported higher EQ-5D-5L Index scores vs PBO: mean 0.82, 0.81, and 0.71 in the Obe-50, Obe-25 and PBO groups, respectively (Obe-50:Δ0.10 and Obe-25:Δ0.09, p < 0.0001).” (opens the source at this quote in a new tab)

“At Week 8, a greater proportion of Obe-treated pts had a MWPC on the EQ-5D-5L Index: 41.0% for Obe-50 and 38.9% for Obe-25 vs 28.5% for PBO (Obe-50:Δ12.59 and Obe-25:Δ10.36, p < 0.01).” (opens the source at this quote in a new tab)

Safety results
Treatment-emergent adverse events at Week 8 reported by the company
Event, n (%)Placebo (N=158)Obefazimod 25 mg (N=160)Obefazimod 50 mg (N=318)
Any TEAE“84 (53.2%)”“75 (46.9%)”“189 (59.4%)”
TEAE leading to study drug discontinuation“6 (3.8%)”“0 (0.0%)”“17 (5.3%)”
Serious TEAE“3 (1.9%)”“1 (0.6%)”“14 (4.4%)”
Malignancy“0 (0.0%)”“0 (0.0%)”“1 (0.3%)”
Serious or severe (grade 3 or higher) infections and opportunistic infections“1 (0.6%)”“1 (0.6%)”“2 (0.6%)”
Non-serious adverse events at a 5% reporting threshold in the posted results
Pooled ABTECT-1 and ABTECT-2: adverse events leading to study drug discontinuation
Event, n (%)Obefazimod 50 mg (n=636)Obefazimod 25 mg (n=319)Placebo (n=317)
Ulcerative colitis“7 (1.1)”“2 (0.6)”“7 (2.2)”
Headache“7 (1.1)”“1 (0.3)”“0”
Vomiting“4 (0.6)”“1 (0.3)”“0”
Nausea“3 (0.5)”“1 (0.3)”“0”
Pancreatitis acute“2 (0.3)”“1 (0.3)”“1 (0.3)”
Study limitations
Summary: study limitations
  • Duration and comparator: ABTECT-1 compared obefazimod 25 mg and 50 mg once daily with placebo for 8 weeks, with adverse events collected for up to 12 weeks. It has no active comparator, and the durability of response is assessed only in the separate ABTECT Maintenance trial, which enrolled Week 8 responders from both induction trials.
  • Sources of the results: the results come from the ClinicalTrials.gov posting (first posted September 10, 2026), congress abstracts and posters, and company press releases and filings. The counts differ between sources: the registry lists 639 participants enrolled, the participant flow starts with 318, 161, and 160 by arm, and the Full Analysis Set holds 636, because one participant randomized to 25 mg and two randomized to placebo were never dosed.
  • Placebo group and background therapy: randomization was 2:1:1, so the placebo arm holds 158 participants, of whom 4 (2.5%) reached clinical remission at Week 8. Stable oral 5-ASA and oral corticosteroids were allowed, and the protocol states that such background therapy “may be partially effective at controlling UC symptoms”.
  • Population: participants were 16 years or older (18 or older in the EU, the EEA, and Ukraine) with a modified Mayo Score of 5 or more and a centrally read endoscopic subscore of 2 or 3. Isolated proctitis, primary sclerosing cholangitis, creatinine clearance below 60 mL/min, QT prolongation, and HIV infection were exclusions. Of the 636 participants analyzed, 288 (45.3%) had a prior inadequate response to an advanced therapy and 52 had a prior inadequate response to a JAK inhibitor; 48 were 65 years or older, 10 were Black or African American, and 166 were Asian. The registry lists 264 locations.
  • Endpoints for two regulators: the FDA primary endpoint is clinical remission by the modified Mayo Score; for the EMA, endoscopic improvement and symptomatic remission are co-primary endpoints, and symptomatic remission was not multiplicity controlled under the FDA testing scheme. The Form 20-F describes the primary endpoint as requiring a stool frequency subscore “not greater than baseline”, a condition the registry and protocol definitions do not state.
  • Statistical reporting: the posted protocol omits the assumed treatment difference, power, and placebo remission rate behind the sample size of 612 (“difference of at least” is followed by no value). The pooled ABTECT-1 and ABTECT-2 analyses, including the pooled subgroup analyses, report nominal p-values, and the analysis by disease extent is post hoc. Subgroups are small: among participants with prior advanced therapy inadequate response, 6 of 70 (8.6%) receiving 25 mg and 1 of 69 (1.4%) receiving placebo reached clinical remission (p=0.0556).
  • Safety reporting: serious adverse events occurred in 14 of 318 participants (4.40%) receiving 50 mg, 1 of 160 (0.63%) receiving 25 mg, and 3 of 158 (1.90%) receiving placebo; events in the 50 mg arm included one myocardial infarction, one acute pancreatitis, one pancreatitis, and one stage I prostate cancer. Figures differ between company sources: the rate of discontinuation for headache is given as “0%–1.6%” in the UEG Week 2025 abstract and “0-1.1%” in the integrated safety abstract, and pooled headache with 50 mg as 24.1% in a press release and 23.3% (148 of 636) in the integrated safety poster.